You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib

Article metrics

Article menu

Download PDFPDF

Rheumatoid arthritis
Original article
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib

 

Online download statistics by month:

Online download statistics by month: February 2019 to March 2024

AbstractFullPdf
Feb 201913413191
Mar 2019248237116
Apr 201939839592
May 201925224472
Jun 201918917840
Jul 201918217947
Aug 201913813523
Sep 201913713234
Oct 201915314930
Nov 20191009419
Dec 2019847724
Jan 2020978730
Feb 2020666024
Mar 2020605819
Apr 2020423661
May 2020484551
Jun 2020343210
Jul 2020595532
Aug 2020423221
Sep 20201059554
Oct 2020545229
Nov 2020817421
Dec 2020615522
Jan 2021636017
Feb 2021413022
Mar 2021646317
Apr 2021504722
May 2021423825
Jun 2021302517
Jul 2021343014
Aug 2021594428
Sep 202111411111
Oct 202114914537
Nov 202117516820
Dec 202121220728
Jan 202222221812
Feb 202225324922
Mar 202223623316
Apr 202237437018
May 202242041122
Jun 202248048119
Jul 202232832621
Aug 202228227717
Sep 202230130228
Oct 202230229523
Nov 202227126720
Dec 20222722688
Jan 202328828524
Feb 202323323017
Mar 202323122521
Apr 202324423530
May 202327826828
Jun 202316015916
Jul 202318818914
Aug 202319318418
Sep 202314614110
Oct 202315915028
Nov 202323021123
Dec 202316416217
Jan 202416016222
Feb 202429028416
Mar 202429029124
Total10792104731754